It has been reported that GH administration can decrease abdominal visceral fat and trunk fat, increase lean body mass and reduce triglyceride levels, and thus improve NAFLD in GHD patients [10,11]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.